AGD1/USP10/METTL13 complexes enhance cancer stem cells proliferation and diminish the therapeutic effect of docetaxel via CD44 m6A modification in castration resistant prostate cancer
Abstract Background Most patients with prostate cancer inevitably progress to castration-resistant prostate cancer (CRPC), at which stage chemotherapeutics like docetaxel become the first-line treatment. However, chemotherapy resistance typically develops after an initial period of therapeutic effic...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13046-025-03272-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594347833425920 |
|---|---|
| author | Hong Wang Chunli Cui Weiyi Li Hui Wu Jianjun Sha Jiahua Pan Wei Xue |
| author_facet | Hong Wang Chunli Cui Weiyi Li Hui Wu Jianjun Sha Jiahua Pan Wei Xue |
| author_sort | Hong Wang |
| collection | DOAJ |
| description | Abstract Background Most patients with prostate cancer inevitably progress to castration-resistant prostate cancer (CRPC), at which stage chemotherapeutics like docetaxel become the first-line treatment. However, chemotherapy resistance typically develops after an initial period of therapeutic efficacy. Increasing evidence indicates that cancer stem cells confer chemotherapy resistance via exosomes. This study demonstrated that AGD1, derived from prostate cancer stem cells (PCSCs), enhanced the stemness of prostate cancer cells and reduced the therapeutic effect of docetaxel in CRPC. Methods Quantitative real-time PCR (qPCR) was employed to determine the expression levels of AGD1 and METTL13 mRNAs in PCSCs and exosomes. Protein expression levels were examined using western blots and dot blots. The potential functions of AGD1 and METTL13 in CRPC were investigated through cell proliferation assay, Transwell assay, EdU incorporation assays, Annexin V-FITC/PI staining, and sphere formation assays. To uncover the underlying mechanisms of AGD1, RNA pull-down assay, RIP, co-Immunoprecipitation (co-IP), mass spectrometry (MS), Methylated RNA immunoprecipitation (MeRIP) and single-base elongation and ligation-based qPCR amplification method (SELECT) were performed. The effects of AGD1 and METTL13 on CRPC development and metastasis under docetaxel treatment were analyzed using a xenograft mouse model and an organoid model. Additionally, liposomal-chitosan nanocomplex drug delivery systems were designed to explore AGD1’s role in regulating docetaxel treatment resistance in CRPC. Results AGD1 expression was upregulated in PCSCs and exosomes. Downregulating AGD1 enhanced the sensitivity of CRPC to docetaxel treatment by inhibiting their stemness, with the reverse also being true. RNA pull-down, combined with MS, co-IP and RIP assays, demonstrated that AGD1 binds to METTL13 and USP10, forming a complex that facilitates METTL13 protein accumulation through USP10-induced deubiquitination. MeRIP assay and SELECT assay revealed that METTL13 transcriptionally controls the mRNA decay of CD44 via m6A methylation. Additionally, this process activates the pSTAT3/PI3K-AKT signaling pathway. Organoid models and liposomal-chitosan nanocomplex drug delivery systems showed that reducing AGD1 expression enhanced the therapeutic effect of docetaxel in CRPC. Conclusions AGD1 mediates the stemness and apoptosis of PCSCs and promotes docetaxel treatment resistance by enhancing tumor growth and metastasis through USP10/METTL13-mediated CD44 mRNA decay in CRPC. |
| format | Article |
| id | doaj-art-7f12ccbbeb9940eebed75fff29d8eec7 |
| institution | Kabale University |
| issn | 1756-9966 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Experimental & Clinical Cancer Research |
| spelling | doaj-art-7f12ccbbeb9940eebed75fff29d8eec72025-01-19T12:43:21ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662025-01-0144111910.1186/s13046-025-03272-3AGD1/USP10/METTL13 complexes enhance cancer stem cells proliferation and diminish the therapeutic effect of docetaxel via CD44 m6A modification in castration resistant prostate cancerHong Wang0Chunli Cui1Weiyi Li2Hui Wu3Jianjun Sha4Jiahua Pan5Wei Xue6Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Special Examinations, Qingdao Women and Children HospitalDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji UniversityDepartment of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of MedicineAbstract Background Most patients with prostate cancer inevitably progress to castration-resistant prostate cancer (CRPC), at which stage chemotherapeutics like docetaxel become the first-line treatment. However, chemotherapy resistance typically develops after an initial period of therapeutic efficacy. Increasing evidence indicates that cancer stem cells confer chemotherapy resistance via exosomes. This study demonstrated that AGD1, derived from prostate cancer stem cells (PCSCs), enhanced the stemness of prostate cancer cells and reduced the therapeutic effect of docetaxel in CRPC. Methods Quantitative real-time PCR (qPCR) was employed to determine the expression levels of AGD1 and METTL13 mRNAs in PCSCs and exosomes. Protein expression levels were examined using western blots and dot blots. The potential functions of AGD1 and METTL13 in CRPC were investigated through cell proliferation assay, Transwell assay, EdU incorporation assays, Annexin V-FITC/PI staining, and sphere formation assays. To uncover the underlying mechanisms of AGD1, RNA pull-down assay, RIP, co-Immunoprecipitation (co-IP), mass spectrometry (MS), Methylated RNA immunoprecipitation (MeRIP) and single-base elongation and ligation-based qPCR amplification method (SELECT) were performed. The effects of AGD1 and METTL13 on CRPC development and metastasis under docetaxel treatment were analyzed using a xenograft mouse model and an organoid model. Additionally, liposomal-chitosan nanocomplex drug delivery systems were designed to explore AGD1’s role in regulating docetaxel treatment resistance in CRPC. Results AGD1 expression was upregulated in PCSCs and exosomes. Downregulating AGD1 enhanced the sensitivity of CRPC to docetaxel treatment by inhibiting their stemness, with the reverse also being true. RNA pull-down, combined with MS, co-IP and RIP assays, demonstrated that AGD1 binds to METTL13 and USP10, forming a complex that facilitates METTL13 protein accumulation through USP10-induced deubiquitination. MeRIP assay and SELECT assay revealed that METTL13 transcriptionally controls the mRNA decay of CD44 via m6A methylation. Additionally, this process activates the pSTAT3/PI3K-AKT signaling pathway. Organoid models and liposomal-chitosan nanocomplex drug delivery systems showed that reducing AGD1 expression enhanced the therapeutic effect of docetaxel in CRPC. Conclusions AGD1 mediates the stemness and apoptosis of PCSCs and promotes docetaxel treatment resistance by enhancing tumor growth and metastasis through USP10/METTL13-mediated CD44 mRNA decay in CRPC.https://doi.org/10.1186/s13046-025-03272-3AGD1USP10METTL13m6AUbiquitination |
| spellingShingle | Hong Wang Chunli Cui Weiyi Li Hui Wu Jianjun Sha Jiahua Pan Wei Xue AGD1/USP10/METTL13 complexes enhance cancer stem cells proliferation and diminish the therapeutic effect of docetaxel via CD44 m6A modification in castration resistant prostate cancer Journal of Experimental & Clinical Cancer Research AGD1 USP10 METTL13 m6A Ubiquitination |
| title | AGD1/USP10/METTL13 complexes enhance cancer stem cells proliferation and diminish the therapeutic effect of docetaxel via CD44 m6A modification in castration resistant prostate cancer |
| title_full | AGD1/USP10/METTL13 complexes enhance cancer stem cells proliferation and diminish the therapeutic effect of docetaxel via CD44 m6A modification in castration resistant prostate cancer |
| title_fullStr | AGD1/USP10/METTL13 complexes enhance cancer stem cells proliferation and diminish the therapeutic effect of docetaxel via CD44 m6A modification in castration resistant prostate cancer |
| title_full_unstemmed | AGD1/USP10/METTL13 complexes enhance cancer stem cells proliferation and diminish the therapeutic effect of docetaxel via CD44 m6A modification in castration resistant prostate cancer |
| title_short | AGD1/USP10/METTL13 complexes enhance cancer stem cells proliferation and diminish the therapeutic effect of docetaxel via CD44 m6A modification in castration resistant prostate cancer |
| title_sort | agd1 usp10 mettl13 complexes enhance cancer stem cells proliferation and diminish the therapeutic effect of docetaxel via cd44 m6a modification in castration resistant prostate cancer |
| topic | AGD1 USP10 METTL13 m6A Ubiquitination |
| url | https://doi.org/10.1186/s13046-025-03272-3 |
| work_keys_str_mv | AT hongwang agd1usp10mettl13complexesenhancecancerstemcellsproliferationanddiminishthetherapeuticeffectofdocetaxelviacd44m6amodificationincastrationresistantprostatecancer AT chunlicui agd1usp10mettl13complexesenhancecancerstemcellsproliferationanddiminishthetherapeuticeffectofdocetaxelviacd44m6amodificationincastrationresistantprostatecancer AT weiyili agd1usp10mettl13complexesenhancecancerstemcellsproliferationanddiminishthetherapeuticeffectofdocetaxelviacd44m6amodificationincastrationresistantprostatecancer AT huiwu agd1usp10mettl13complexesenhancecancerstemcellsproliferationanddiminishthetherapeuticeffectofdocetaxelviacd44m6amodificationincastrationresistantprostatecancer AT jianjunsha agd1usp10mettl13complexesenhancecancerstemcellsproliferationanddiminishthetherapeuticeffectofdocetaxelviacd44m6amodificationincastrationresistantprostatecancer AT jiahuapan agd1usp10mettl13complexesenhancecancerstemcellsproliferationanddiminishthetherapeuticeffectofdocetaxelviacd44m6amodificationincastrationresistantprostatecancer AT weixue agd1usp10mettl13complexesenhancecancerstemcellsproliferationanddiminishthetherapeuticeffectofdocetaxelviacd44m6amodificationincastrationresistantprostatecancer |